Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19756273 | 0.90 | KDM4E (0.36) | KDM4EALDH1A1PKMGRIA1MEN1 | |
| SCHEMBL16589732 | 0.85 | KDM4E (0.36) | KDM4EALDH1A1PKMGRIA1DNM1 | |
| SCHEMBL16589713 | 0.83 | GRIA1 (0.37) | KDM4EALDH1A1PKMGRIA1DNM1 | |
| SCHEMBL16589717 | 0.81 | KDM4E (0.37) | KDM4EALDH1A1PKMGRIA1MEN1 | |
| SCHEMBL24328660 | 0.81 | KDM4E (0.34) | KDM4EALDH1A1PKMDNM1MMP1 | |
| SCHEMBL16589716 | 0.80 | KDM4E (0.36) | KDM4EALDH1A1PKMGRIA1MEN1 | |
| SCHEMBL16589720 | 0.80 | CCKBR (0.44) | — | |
| SCHEMBL21285412 | 0.79 | KDM4E (0.33) | KDM4EALDH1A1PKMDNM1MMP1 | |
| SCHEMBL16589719 | 0.79 | CAPN1 (0.44) | KDM4EALDH1A1PKMMMP1 | |
| SCHEMBL16589728 | 0.76 | CTSS (0.44) | KDM4EALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | NPR1, NPR3, CNP | KDM4E 3833/4885ALDH1A1 4718/4885PKM 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.